logo
Plus   Neg
Share
Email

Genentech : Late-stage Study Shows Xofluza Prevents Influenza Infection

Genentech, a member of the Roche Group (RHHBY), said Tuesday that Phase III study, dubbed BLOCKSTONE, showed Xofluza was effective at preventing influenza infection.

The company noted that the late-stage Blockstone study, conducted by Shionogi & Co., met its primary endpoint showing that people exposed to a household member with influenza and treated preventatively with Xofluza were significantly less likely to develop the disease compared to those treated with placebo. In addition, Xofluza was well tolerated with no safety signals identified.

Xofluza is currently approved in Japan for the treatment of influenza types A and B in children, adolescents and adults, and in the U.S. for the treatment of acute, uncomplicated influenza in people 12 years of age and older.

Recently, the U.S. Food and Drug Administration accepted a supplemental New Drug Application for Xofluza as a one-dose oral treatment for people at high risk of complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity or heart disease - for these people the flu can be particularly serious or deadly.

It is expected that the FDA will decide on whether to approve the additional indication by November 4, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has delayed the worldwide launch of its Surface Earbuds till Spring 2020. The $249 wireless earbuds were originally expected to launch this year. The delay is a setback in Microsoft's attempt to compete with Apple's latest earbuds, AirPods Pro, which has a new design and features active noise cancellation. General Motors Co. (GM) is hiring for new workforce, after cutting about some 4,000 salaried employees early this year. According to Detroit Free Press, the auto giant is hiring for a new workforce as the company invests more money to develop electric and self-driving vehicles. Earlier this year,... Australia's Federal Court has ruled in favor of more than 1,000 women in a landmark class-action lawsuit against Johnson & Johnson after they suffered severe pain and complications from the healthcare giant's pelvic mesh implants. Johnson & Johnson and its subsidiary Ethicon were accused of hiding the risks of its pelvic mesh products.
Follow RTT
>